What is the infectivity of SARS-CoV-2 Omicron BA.2.75 variant?

In a recent study posted to the bioRxiv* preprint server, researchers assessed the infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2.75 variant compared to pre-existing variants.

Study: SARS-CoV-2 Omicron BA.2.75 variant may be much more infective than preexisting variants. Image Credit: Fit Ztudio/Shutterstock
Study: SARS-CoV-2 Omicron BA.2.75 variant may be much more infective than preexisting variants. Image Credit: Fit Ztudio/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

As of July 2022, the SARS-CoV-2 Omicron BA.5 variant has become an epidemic in Japan. The recently emerged Omicron BA.2.75 has further concerned the world. Studies have developed a mathematical model to predict and compare the infectivities of different SARS-CoV-2 variants such as Wuhan, Alpha, Beta, Gamma, Delta, and Omicron BA.1 and BA.2 variants. 

About the study 

In the present study, researchers predicted the comparative risk of infection by recently emerging variants such as the SARS-CoV-2 Omicron BA.2.75 variant compared to that against preexisting variants.

The team assessed the evolutionary distance of viral spike (S) genes between the Wuhan variant and Omicron BA.4, BA.5, or BA.2.75. The S gene sequences were collected by searching the EpiCoV database of the Global Initiative on Sharing All Influenza Data (GISAID) for the one having a complete S gene sequence. The docking affinity associated with the receptor-binding domain (RBD) of each S protein of these variants with angiotensin-converting enzyme-2 (ACE-2) was assessed via cluster analysis and docking simulation.

The amino acid sequences related to the S proteins were collected from the CoVariants website that classified the variants as per Nextstrain clades, wherein the Omicron BA.4 variant was classified as 22A, Omicron BA.5 as 22B, and Omicron BA.2.75 as 22D. Since BA.4 and BA.5 had similar S proteins, the S gene and amino acid sequences were grouped together for the study.      

Results

The study results showed that the SARS-CoV-2 variants that had a longer evolutionary distance from the SARS-CoV-2 Wuhan variant were more likely to lead to an epidemic. The Omicron BA.2.75 variant was found to have the highest docking affinity of the viral S protein with the ACE2 protein. Compared to the Omicron BA.2 variant, while BA.4 and BA.5 had longer S gene evolutionary distances, the docking affinity observed was lower.

Furthermore, compared to BA.2, BA.2.75 displayed longer evolutionary distances along with higher docking affinity. This indicated that BA.2.75 has a higher ability to enter host cells, while the currently available SARS-CoV-2 vaccines are less effective against this variant. 

Conclusion

The study findings showed that the infectivity of the SARS-CoV-2 Omicron BA.2.75 variant was significantly high due to the long S gene evolutionary distance and the docking simulation for the viral S protein with ACE2. The researchers believe that Omicron BA.2.75 poses a higher risk of causing a global health crisis.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 15 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Bhavana Kunkalikar

Written by

Bhavana Kunkalikar

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kunkalikar, Bhavana. (2023, May 15). What is the infectivity of SARS-CoV-2 Omicron BA.2.75 variant?. News-Medical. Retrieved on December 23, 2024 from https://www.news-medical.net/news/20220830/What-is-the-infectivity-of-SARS-CoV-2-Omicron-BA275-variant.aspx.

  • MLA

    Kunkalikar, Bhavana. "What is the infectivity of SARS-CoV-2 Omicron BA.2.75 variant?". News-Medical. 23 December 2024. <https://www.news-medical.net/news/20220830/What-is-the-infectivity-of-SARS-CoV-2-Omicron-BA275-variant.aspx>.

  • Chicago

    Kunkalikar, Bhavana. "What is the infectivity of SARS-CoV-2 Omicron BA.2.75 variant?". News-Medical. https://www.news-medical.net/news/20220830/What-is-the-infectivity-of-SARS-CoV-2-Omicron-BA275-variant.aspx. (accessed December 23, 2024).

  • Harvard

    Kunkalikar, Bhavana. 2023. What is the infectivity of SARS-CoV-2 Omicron BA.2.75 variant?. News-Medical, viewed 23 December 2024, https://www.news-medical.net/news/20220830/What-is-the-infectivity-of-SARS-CoV-2-Omicron-BA275-variant.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cardiovascular risks post-COVID-19 vaccination: Key findings